Page 87 - e-CPG-SLE-8_5_24
P. 87
Management of Systemic Lupus Erythematosus
Appendix 8
FREQUENCY OF MONITORING PATIENTS WITH SLE
Patients with
active disease Patients with stable/
At first low disease activity
Assessments should be reviewed
visit should be reviewed
at least every every 6 - 12 months
1 - 3 months
Clinical
History
Vital signs (blood
pressure, heart rate,
weight)
Clinical examination
Drug review
Blood tests
Full blood count
Renal profile
Liver function test
CRP a a
ESR
Bone profile (calcium, a a a
phosphate, ALP)
Vitamin D3 a - a
Immunology/serology
ANA - -
Anti-dsDNA a a
C3/C4 levels a
aPL (LA, aCL, aβ2GPI) a a,p
ENA (anti-Ro/La, anti-RNP, a a,p
anti-Sm antibodies)
Immunoglobulin A, G, M a a a
Direct Coombs’ test a a
Urine
UFEME
Urine random protein:
creatinine ratio OR a a a
24-hour urine protein
Other investigation
Culture a a a
Biopsy (e.g. skin, kidney) a a a
Neurophysiology (e.g. a a a
nerve conduction study,
EMG) a a a
ECG a a a
Echocardiogram a a a
Imaging
Chest X-ray a a a
Others (US, CT, MRI) a a a
70
Patients with
active disease Patients with stable/
At first low disease activity
Assessments should be reviewed
visit should be reviewed
at least every every 6 - 12 months
1 - 3 months
Modifiable cardiovascular
risk factors
Hypertension
Dyslipidaemia a a
Diabetes mellitus
High BMI
Smoking/vaping